

## Program Overview

### International Society of Amyloidosis

The **International Society of Amyloidosis (ISA)** is a non-profit organization of Scientists and Physicians engaged in research, teaching, or practice in connection with amyloid and amyloidosis. The aims of our Society are to promote research, education, clinical studies (including diagnosis and treatment), conferences and symposia on all aspects of amyloidosis worldwide.

#### ISA Membership

The International Society of Amyloidosis is the professional home for scientists and physicians engaged in research, teaching or practice in connection with amyloid and amyloidosis. Student memberships are available at discounted rates.

Any person who works in connection with amyloidosis, but is not directly involved in the medical diagnosis and treatment of amyloidosis patients or academic research, is eligible to be considered for affiliate membership. Employees of pharmaceutical companies, medical device companies or other companies with commercial interests, as well as employees of nonprofit patient support or advocacy organizations, may apply for affiliate memberships. Amyloidosis patients, their family members and care partners are eligible to apply for patient/care partner memberships.

#### Educational Programs

##### Virtual Case Discussions

ISA holds virtual 90-minute case discussions on a periodic basis, with the goals of increasing awareness of amyloidosis around the globe and showcasing how the latest diagnostic methods and treatment options can be applied to real-life cases. These discussions, held in English and Spanish, are open to anyone engaged in the diagnosis and management of amyloidosis. Case discussions in other languages may be added.

##### Scientific Workshops


ISA holds small scientific workshops bringing together basic scientists and clinical experts to define major unsolved questions in the field of amyloidosis, and to develop ideas and networks to solve them.

##### ISA 2026 (XX International Symposium on Amyloidosis)

ISA 2026 will be held in Uruguay in September 2026. Planning is underway and more details will be available soon!

#### Presidential Awards and Travel Grants

To support the academic careers of young scientists pursuing careers in amyloidosis research, ISA offers Presidential Awards (cash awards for young investigators with the best abstracts for each International Symposium) and travel grants (to attend scientific meetings such as ISA's Scientific Workshops). ISA funded 12 Presidential Awards for ISA 2024.



## Guidelines

ISA Working Groups have developed the following guidelines for diagnosis and treatment of amyloidosis:

- Tissue Biopsy for the Diagnosis of Amyloidosis: Experience From Some Centres
- Guidelines for High Dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis
- Guidelines for Non-transplant Chemotherapy for Treatment of Systemic AL Amyloidosis
- Guidelines and New Directions in the Therapy and Monitoring of ATTRv Amyloidosis

Work is underway to develop additional guidelines:

- Light Chain Sequencing & Analysis
- Diagnosis and Treatment of ATTRwt Amyloidosis
- Diagnosis and Treatment of AA Amyloidosis
- Tissue Diagnosis

## Amyloid Nomenclature

ISA's Nomenclature Committee works to maintain, update and recommend a uniform amyloid nomenclature and terminology to support precise and consistent scientific communications in the field.

## Genetics External Quality Assessment Scheme

ISA's Genetics EQA Working Group is working with the European Molecular Genetics Quality Network (EMQN) to develop a new worldwide external quality assessment (EQA) scheme for ATTRv amyloidosis (including other genes associated with hereditary amyloidosis). ISA's goal for this work is to help in establishing best practice guidelines for molecular diagnosis in ATTRv amyloidosis.

## Amyloid Typing Survey

The International Society of Amyloidosis has completed a survey on how amyloid typing is conducted around the world. The resulting data allowed ISA to develop a real-life overview of typing strategies worldwide and identify barriers to accurate typing. The Society is evaluating measures to facilitate and support referrals for amyloid typing.

## 2024-2025 Amyloidosis Fellowships

In collaboration with Pfizer, ISA is supporting five cardiac amyloidosis fellowships for 2023-2024. For 2024-2025 and beyond, ISA has broadened support to include multiple sponsors, and has expanded the fellowships to address other types of amyloidosis.

## Editorial Support for *Amyloid*, ISA's Official Journal

The Board of Directors of the International Society of Amyloidosis appoints the Editor-in-Chief for the Society's official journal, *Amyloid: The Journal of Protein Folding Disorders*. The journal's 2022 Impact Factor is 5.5.